0000902664-25-003593.txt : 20250814 0000902664-25-003593.hdr.sgml : 20250814 20250814115824 ACCESSION NUMBER: 0000902664-25-003593 CONFORMED SUBMISSION TYPE: SCHEDULE 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250814 DATE AS OF CHANGE: 20250814 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Sagimet Biosciences Inc. CENTRAL INDEX KEY: 0001400118 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 205991472 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-94156 FILM NUMBER: 251216127 BUSINESS ADDRESS: STREET 1: 155 BOVET RD., SUITE 303 CITY: SAN MATEO STATE: CA ZIP: 94402 BUSINESS PHONE: (650) 561-8600 MAIL ADDRESS: STREET 1: 155 BOVET RD., SUITE 303 CITY: SAN MATEO STATE: CA ZIP: 94402 FORMER COMPANY: FORMER CONFORMED NAME: 3-V Biosciences, Inc. DATE OF NAME CHANGE: 20070521 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Woodline Partners LP CENTRAL INDEX KEY: 0001784547 ORGANIZATION NAME: EIN: 831749088 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SCHEDULE 13G BUSINESS ADDRESS: STREET 1: 4 EMBARCADERO CENTER STREET 2: SUITE 3450 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 BUSINESS PHONE: 415-801-4550 MAIL ADDRESS: STREET 1: 4 EMBARCADERO CENTER STREET 2: SUITE 3450 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 FORMER COMPANY: FORMER CONFORMED NAME: Woodline Partners DATE OF NAME CHANGE: 20190805 SCHEDULE 13G 1 primary_doc.xml SCHEDULE 13G 0001784547 XXXXXXXX LIVE Series A Common Stock, par value $0.0001 per share 06/30/2025 0001400118 Sagimet Biosciences Inc. 786700104 155 BOVET RD., SUITE 303 SAN MATEO CA 94402 Rule 13d-1(b) Woodline Partners LP DE 2552536.00 0.00 2552536.00 0.00 2552536.00 N 8.3 IA PN Sagimet Biosciences Inc. 155 Bovet Road, Suite 303, San Mateo, CA 94402 This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of series A common stock, par value $0.0001 per share ("Series A Common Stock") of Sagimet Biosciences Inc. (the "Company") directly held by the Woodline Fund. The filing of this statement should not be construed as an admission that the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Series A Common Stock reported herein. The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111. Woodline Partners is a Delaware limited partnership. N IA The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of approximately 30,674,855 shares of Series A Common Stock outstanding as of May 2, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission on May 8, 2025. 8.3% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference. Y N See Item 2(a). Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Woodline Partners LP /s/ Erin Mullen 08/14/2025